AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

02 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

26 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET

20 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film

11 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

15 Jun 2022 15:22:33 By Nasdaq GlobeNewswire

Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering

08 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference

07 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering

06 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces CEO Transition

17 May 2022 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

10 May 2022 07:00:03 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

03 May 2022 16:40:58 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET

18 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

13 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

12 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis

17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance

08 Mar 2022 15:56:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

28 Feb 2022 19:33:43 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

25 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

24 Feb 2022 20:26:14 By Nasdaq GlobeNewswire